DGAP-News: Press Release: 4SC presents summary of biomarker and patient subgroup analysis of prognostic factors for …

DGAP-News: 4SC AG / Key word(s): Miscellaneous Press Release: 4SC presents summary of biomarker and patient subgroup analysis of prognostic factors for survival in advanced HCC

30.09.2013 / 07:30

---------------------------------------------------------------------

Press Release

4SC presents summary of biomarker and patient subgroup analysis of prognostic factors for survival in advanced HCC

- Baseline and biomarker characteristics of advanced HCC patients identified that have an impact on overall survival (OS) and are suitable as enrollment or stratification criteria in upcoming pivotal HCC programme with resminostat

- Novel potentially predictive biomarker ZFP64 identified in both, in HCC and in Hodgkin Lymphoma (HL) patients: high baseline expression of ZFP64 observed in about 2/3 of patients correlates with doubling of median OS under resminostat treatment compared to low ZFP64 expression

- Pharmacodynamic activity of resminostat on ZFP64 confirmed in patients and cell lines: HDAC inhibition by resminostat treatment leads to down-regulation of ZFP64, in peripheral blood of HCC patients

- Further information about proposed role of biomarker ZFP64 in HCC tumour progression presented

- Poster presentation at ECCO 2013 conference, 30 Sept. 2013, Amsterdam

More here:
DGAP-News: Press Release: 4SC presents summary of biomarker and patient subgroup analysis of prognostic factors for ...

Related Posts

Comments are closed.